ストックスクリーナーアプリを入手
1.88
1.33%
0.00
前日終値:
$1.88
開ける：
$1.91
24時間の取引高:
866.60K
Relative Volume:
1.47
時価総額：
$86.89M
収益：
$19.94M
当期純損益:
$-37.37M
株価収益率:
-1.8077
EPS:
-1.04
ネットキャッシュフロー:
$-33.38M
1週間 パフォーマンス:
-0.78%
1か月 パフォーマンス:
+39.05%
6か月 パフォーマンス:
+164.69%
1年 パフォーマンス:
+3.53%
1日の値動き範囲:
$1.845
$1.9371
1週間の範囲:
$1.82
$2.15
52週間の値動き範囲:
$0.595
$4.18
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
名前
Werewolf Therapeutics Inc
セクター
電話
617-952-0555
住所
200 TALCOTT AVENUE, WATERTOWN
HOWL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.90 | 85.97M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
415.50 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.33 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
570.48 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.14 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
336.58 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-04-03 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-24 | 開始されました | Wedbush | Outperform |
| 2023-06-06 | 再開されました | Jefferies | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-25 | 開始されました | Evercore ISI | Outperform |
| 2021-05-25 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-25 | 開始されました | Jefferies | Buy |
| 2021-05-25 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Werewolf Therapeutics Inc (HOWL) 最新ニュース
How high can Werewolf Therapeutics Inc. stock goEarnings Summary Report & Reliable Intraday Trade Alerts - newser.com
Werewolf Therapeutics receives FDA Fast Track for melanoma therapy By Investing.com - Investing.com Nigeria
Werewolf Therapeutics Says Investigational Melanoma Therapy WTX-124 Receives US FDA Fast Track Designation - MarketScreener
Werewolf Therapeutics receives fast track designation from the U.S. FDA for WTX-124, an investigational therapy for the treatment of cancer - MarketScreener
Werewolf Therapeutics Receives Fast Track Designation from - GlobeNewswire
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - Stock Titan
Werewolf Therapeutics Faces Nasdaq Compliance Challenge - TipRanks
Werewolf Therapeutics notifies Nasdaq of audit committee noncompliance after board member’s passing - Investing.com
Using flow based indicators on Werewolf Therapeutics Inc.Market Growth Summary & Risk Managed Trade Strategies - newser.com
Will earnings trigger a reversal in Werewolf Therapeutics Inc.2025 Institutional Moves & Long-Term Safe Investment Ideas - newser.com
Werewolf Therapeutics Inc. stock chart pattern explainedWeekly Trade Report & AI Enhanced Trade Execution Alerts - newser.com
Intraday pattern recognizer results for Werewolf Therapeutics Inc.Fed Meeting & Weekly High Return Stock Forecasts - newser.com
Will Werewolf Therapeutics Inc. stock maintain dividend yieldJuly 2025 Short Interest & Verified High Yield Trade Plans - newser.com
Jefferies Initiates Werewolf Therapeutics(HOWL.US) With Buy Rating, Announces Target Price $4 - 富途牛牛
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - GlobeNewswire
Werewolf Therapeutics to Present Innovative Research at SITC 40th Annual Meeting - Quiver Quantitative
3 Posters: Werewolf Therapeutics to Present WTX-124, mWTX-330 Research at SITC Nov 5-9 - Stock Titan
Published on: 2025-09-30 05:19:05 - newser.com
Goldman Sachs Group Inc. Has $109,000 Stock Holdings in Werewolf Therapeutics, Inc. $HOWL - Defense World
Published on: 2025-09-30 01:50:53 - newser.com
What analysts say about Werewolf Therapeutics Inc stockMomentum Trading Signals & Outstanding Growth Stocks - earlytimes.in
Earnings visualization tools for Werewolf Therapeutics Inc.Portfolio Performance Summary & Fast Moving Stock Trade Plans - newser.com
What institutional flow reveals about Werewolf Therapeutics Inc.Market Risk Analysis & Risk Controlled Swing Alerts - newser.com
Werewolf Therapeutics Inc (HOWL) 財務データ
収益
当期純利益
現金流量
EPS
0.91%
1.10%
大文字化:
|
ボリューム (24 時間):